Avidity Biosciences (RNA) News Today $42.18 -7.79 (-15.59%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Los Angeles Capital Management LLC Takes Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Los Angeles Capital Management LLC bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 14,376 shares of the biotechnology company's stock, valued atNovember 17 at 3:34 AM | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Stock Price Down 7.8% - Should You Sell?November 17 at 2:49 AM | americanbankingnews.com44,898 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by State of New Jersey Common Pension Fund DState of New Jersey Common Pension Fund D bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 44,898 shares ofNovember 16 at 4:22 AM | marketbeat.comAssetmark Inc. Invests $566,000 in Avidity Biosciences, Inc. (NASDAQ:RNA)Assetmark Inc. bought a new position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 12,319 shares of the biotechnology company's stock, valued at apNovember 16 at 3:33 AM | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Stock Price Down 7.8% - Here's WhyAvidity Biosciences (NASDAQ:RNA) Stock Price Down 7.8% - What's Next?November 15 at 1:12 PM | marketbeat.comUS Bancorp DE Cuts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)US Bancorp DE trimmed its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 91.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,244 shares of the biotechnologyNovember 14 at 3:02 AM | marketbeat.comAvidity Biosciences’ Strategic Expansion in Precision Cardiology and siRNA Innovation Justifies Buy RatingNovember 13, 2024 | markets.businessinsider.comAssessing Avidity Biosciences: Insights From 10 Financial AnalystsNovember 13, 2024 | benzinga.comAvidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' NewsNovember 13, 2024 | msn.comAvidity Biosciences jumps 16%; reaches all-time highNovember 13, 2024 | seekingalpha.comAvidity Biosciences (RNA) Gets a Buy from BarclaysNovember 13, 2024 | markets.businessinsider.comAvidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' NewsNovember 13, 2024 | investors.comAvidity Biosciences (NASDAQ:RNA) Hits New 52-Week High - Should You Buy?Avidity Biosciences (NASDAQ:RNA) Reaches New 1-Year High - Still a Buy?November 13, 2024 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Avidity Biosciences (NASDAQ:RNA)Needham & Company LLC reaffirmed a "buy" rating and issued a $60.00 price target on shares of Avidity Biosciences in a research note on Wednesday.November 13, 2024 | marketbeat.comPromising Outlook for Avidity Biosciences: Strategic Focus on Genetic Targeting and Innovative AOC TechnologyNovember 13, 2024 | markets.businessinsider.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from AnalystsShares of Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) have received an average recommendation of "Buy" from the nine ratings firms that are currently covering the company, Marketbeat reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12-monthNovember 13, 2024 | marketbeat.comBuy Rating Affirmed for Avidity Biosciences Amid Precision Cardiology AdvancementsNovember 13, 2024 | markets.businessinsider.comAvidity Biosciences Unveils Advances in Cardiology ResearchNovember 13, 2024 | markets.businessinsider.comAvidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology InnovationsNovember 12, 2024 | prnewswire.comAvidity Biosciences’ Clinical Advancements Positioning for Regulatory SuccessNovember 12, 2024 | markets.businessinsider.comFiera Capital Corp Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)Fiera Capital Corp purchased a new stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 431,210 shares of the biotechnology company's stock, valued at approNovember 9, 2024 | marketbeat.comAvidity Biosciences: Strategic Advancements and Strong Pipeline Support Buy RatingNovember 9, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Avidity Biosciences (RNA) and MoonLake Immunotherapeutics (MLTX)November 9, 2024 | markets.businessinsider.comRNA Avidity Biosciences, Inc.November 7, 2024 | seekingalpha.comAvidity Biosciences Reports Third Quarter 2024 Financial Results and Recent HighlightsNovember 7, 2024 | prnewswire.comAvidity Biosciences (NASDAQ:RNA) Trading 6.5% Higher - Should You Buy?Avidity Biosciences (NASDAQ:RNA) Trading Up 6.5% - Should You Buy?November 4, 2024 | marketbeat.comAvidity Biosciences price target raised to $65 from $60 at ChardanNovember 1, 2024 | markets.businessinsider.comAvidity Biosciences: Strategic Advances and Promising Progress Justify Buy RatingNovember 1, 2024 | markets.businessinsider.comAvidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024October 31, 2024 | prnewswire.comAvidity Biosciences' (RNA) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $60.00 price target on shares of Avidity Biosciences in a research report on Thursday.October 31, 2024 | marketbeat.comChardan Capital Raises Avidity Biosciences (NASDAQ:RNA) Price Target to $65.00Chardan Capital lifted their price target on Avidity Biosciences from $60.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday.October 30, 2024 | marketbeat.comChina Universal Asset Management Co. Ltd. Has $1.04 Million Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)China Universal Asset Management Co. Ltd. lifted its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 100.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,526 shares of the biotecOctober 30, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Director Arthur A. Levin Sells 5,000 SharesOctober 24, 2024 | insidertrades.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Director Sells 5,000 Shares of StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) Director Arthur A. Levin sold 5,000 shares of the firm's stock in a transaction on Monday, October 21st. The stock was sold at an average price of $46.63, for a total value of $233,150.00. Following the completion of the transaction, the director now directly owns 14,830 shares of the company's stock, valued at $691,522.90. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.October 23, 2024 | marketbeat.comAvidity Biosciences price target raised to $78 from $56 at TD CowenOctober 22, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Avidity Biosciences (RNA)October 22, 2024 | markets.businessinsider.comIn-Depth Examination Of 10 Analyst Recommendations For Avidity BiosciencesOctober 21, 2024 | benzinga.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 21, 2024 | prnewswire.comTD Cowen Boosts Avidity Biosciences (NASDAQ:RNA) Price Target to $78.00TD Cowen lifted their price target on shares of Avidity Biosciences from $56.00 to $78.00 and gave the company a "buy" rating in a report on Monday.October 21, 2024 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Shares Down 5.2% - Here's WhyAvidity Biosciences (NASDAQ:RNA) Stock Price Down 5.2% - Time to Sell?October 21, 2024 | marketbeat.comMoss Adams Wealth Advisors LLC Sells 15,717 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Moss Adams Wealth Advisors LLC decreased its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 41.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 22,496 shares of the biotechnology company's stock after selling 15October 19, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from BrokeragesAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) has received a consensus recommendation of "Buy" from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average twelve-mOctober 19, 2024 | marketbeat.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 25,000 Shares of StockOctober 18, 2024 | insidertrades.comAvidity Biosciences (NASDAQ:RNA) Hits New 1-Year High - What's Next?Avidity Biosciences (NASDAQ:RNA) Reaches New 52-Week High - Here's What HappenedOctober 16, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Sees Large Increase in Short InterestAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) was the target of a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 14,770,000 shares, an increase of 23.3% from the September 15th total of 11,980,000 shares. Based on an average trading volume of 1,440,000 shares, the days-to-cover ratio is currently 10.3 days.October 15, 2024 | marketbeat.comSG Americas Securities LLC Sells 83,604 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)SG Americas Securities LLC decreased its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 86.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,675 shares of the biotechnology company's stock after sOctober 15, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Stake Reduced by Millennium Management LLCMillennium Management LLC cut its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 25.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 125,375 shares of the biotechnoloOctober 12, 2024 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Stock Price Down 5.5% After Insider SellingAvidity Biosciences (NASDAQ:RNA) Trading Down 5.5% Following Insider SellingOctober 10, 2024 | marketbeat.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Director Sells 30,000 Shares of StockOctober 10, 2024 | insidertrades.comAvidity Biosciences (NASDAQ:RNA) Trading Up 4.8% - What's Next?Avidity Biosciences (NASDAQ:RNA) Shares Up 4.8% - Here's WhyOctober 8, 2024 | marketbeat.com Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Unveiled: NVIDIA’s "Secret Royalty" Program (Ad)Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip? Click Here to learn how to get in now >>> RNA Media Mentions By Week RNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNA News Sentiment▼0.640.55▲Average Medical News Sentiment RNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNA Articles This Week▼235▲RNA Articles Average Week Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ORIC Pharmaceuticals News Today Nkarta News Today Solid Biosciences News Today BeiGene News Today Moderna News Today Teva Pharmaceutical Industries News Today Summit Therapeutics News Today Genmab A/S News Today Viatris News Today Vaxcyte News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
